Greater Occipital Nerve BlockNCT06997562
Greater Occipital Nerve Blockade and Sphenopalatine Ganglion Blockade in Patients With Episodic Migraine
A study testing Greater occipital nerve blockade and Sphenopalatine ganglion blockade in people with Greater Occipital Nerve Block and Sphenopalatine Ganglion Block, run by New Valley University at 1 site in Egypt.
Trial summary
This study compares the effectiveness of greater occipital nerve blockade and sphenopalatine ganglion blockade in reducing headache intensity, duration, frequency, and disability in patients with episodic migraine. Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Greater Occipital Nerve Block, Sphenopalatine Ganglion Block, Episodic Migraine
- What is being tested?
- Greater occipital nerve blockade and Sphenopalatine ganglion blockade
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 60 participants
- Where
- 1 siteEgypt
- Study dates
- 1 May 2024to 3 May 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Adults aged 18-65 years.
- Both sexes.
- Diagnosed with episodic migraine per the International Classification of Headache Disorders, 3rd edition (ICHD-3).
- Failure to achieve adequate relief with at least one prophylactic migraine treatment.
Who cannot join
- Chronic migraine (≥15 headache days per month).
- History of nerve blocks within the last 6 months.
- Known allergy to anesthetic agents.
- Pregnancy or lactation.
- Active psychiatric conditions affecting compliance.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Comparative Efficacy of Greater Occipital Nerve Blockade and Sphenopalatine Ganglion Blockade in Patients With Episodic Migraine
This study compares the effectiveness of greater occipital nerve blockade and sphenopalatine ganglion blockade in reducing headache intensity, duration, frequency, and disability in patients with episodic migraine.
Read the detailed description
Migraine is a chronic neurological disorder characterized by recurrent headaches, affecting millions globally. Peripheral nerve blocks such as Greater Occipital Nerve (GON) and Sphenopalatine Ganglion (SPG) blockade have emerged as promising non-pharmacologic treatments.
- Being tested
- Greater occipital nerve blockade, Sphenopalatine ganglion blockade
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Greater occipital nerve blockadeOther
Patients will receive greater occipital nerve blockade using 2 mL of 2% lidocaine at the medial one-third of the line between the occipital protuberance and mastoid process.
Sphenopalatine ganglion blockadeOther
Patients will receive greater sphenopalatine ganglion blockade using 2 mL of 2% lidocaine using a transnasal approach with a cotton swab inserted along the superior middle turbinate to the posterior nasopharyngeal wall.
| Study group | Role | What they receive |
|---|---|---|
| Greater occipital nerve blockade group | Experimental | Patients will receive greater occipital nerve blockade using 2 mL of 2% lidocaine at the medial one-third of the line between the occipital protuberance and mastoid process. Receives: Other: Greater occipital nerve blockade |
| Sphenopalatine ganglion blockade group | Experimental | Patients will receive greater sphenopalatine ganglion blockade using 2 mL of 2% lidocaine using a transnasal approach with a cotton swab inserted along the superior middle turbinate to the posterior nasopharyngeal wall. Receives: Other: Sphenopalatine ganglion blockade |
What is being measured
The primary outcome is the main question the study is designed to answer.
Degree of headache intensity
Reduction in headache intensity will be recorded using numeric rating scale (NRS). Each patient will be instructed about pain assessment with NRS score. NRS (0 represents "no pain" while 10 represents "the worst pain imaginable").
Measured: 3 months post-procedure
Secondary outcomes (3)
Migraine disability assessment score
The migraine disability assessment scores are as follows: little or no disability, 5 to 10; moderate disability, 1 to 20; and severe disability, more than 20.
Measured: 3 months post-procedure
Headache duration
Headache duration will be recorded.
Measured: 3 months post-procedure
Headache frequency
Headache frequency will be recorded.
Measured: 3 months post-procedure
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 May 2025
- Study start1 May 2024
- Primary completion3 May 2025
- Study completion3 May 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Greater Occipital Nerve BlockStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 60 participants (actual)
Sponsor and investigators
- Lead sponsor
- New Valley University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Ahmed Omar Twaisy, New Valley University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06997562
- Sponsor's protocol ID
- 20250430007
- Status last verified
- May 2025
- First submitted
- 21 May 2025
- Last updated
- 30 May 2025
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: The data will be available upon a reasonable request from the corresponding author after the end of study for one year.
Study at a glance
From the registry record, last updated by the sponsor on 30 May 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparative Efficacy of Greater Occipital Nerve Blockade and Sphenopalatine Ganglion Blockade in Patients With Episodic Migraine
- ClinicalTrials.gov ID
- NCT06997562
- Acronym / sponsor ID
- 20250430007
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 60 participants (actual)
- Lead sponsor
- New Valley UniversityUniversity, hospital or other
- Study start
- 1 May 2024 (actual)
- Primary completion
- 3 May 2025 (actual)
- Study completion
- 3 May 2025 (actual)
- First posted
- 30 May 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study compares the effectiveness of greater occipital nerve blockade and sphenopalatine ganglion blockade in reducing headache intensity, duration, frequency, and disability in patients with episodic migraine.
Detailed description
Migraine is a chronic neurological disorder characterized by recurrent headaches, affecting millions globally. Peripheral nerve blocks such as Greater Occipital Nerve (GON) and Sphenopalatine Ganglion (SPG) blockade have emerged as promising non-pharmacologic treatments.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Greater occipital nerve blockade group | Experimental | Other: Greater occipital nerve blockadePatients will receive greater occipital nerve blockade using 2 mL of 2% lidocaine at the medial one-third of the line between the occipital protuberance and mastoid process. |
| Sphenopalatine ganglion blockade group | Experimental | Other: Sphenopalatine ganglion blockadePatients will receive greater sphenopalatine ganglion blockade using 2 mL of 2% lidocaine using a transnasal approach with a cotton swab inserted along the superior middle turbinate to the posterior nasopharyngeal wall. |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Adults aged 18-65 years.
- Both sexes.
- Diagnosed with episodic migraine per the International Classification of Headache Disorders, 3rd edition (ICHD-3).
- Failure to achieve adequate relief with at least one prophylactic migraine treatment.
Key exclusion criteria (5 listed)
- Chronic migraine (≥15 headache days per month).
- History of nerve blocks within the last 6 months.
- Known allergy to anesthetic agents.
- Pregnancy or lactation.
- Active psychiatric conditions affecting compliance.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Greater occipital nerve blockadePatients will receive greater occipital nerve blockade using 2 mL of 2% lidocaine at the medial one-third of the line between the occipital protuberance and mastoid process. | Other | Greater occipital nerve blockade group |
| Sphenopalatine ganglion blockadePatients will receive greater sphenopalatine ganglion blockade using 2 mL of 2% lidocaine using a transnasal approach with a cotton swab inserted along the superior middle turbinate to the posterior nasopharyngeal wall. | Other | Sphenopalatine ganglion blockade group |
Primary outcome
Degree of headache intensity
Time frame: 3 months post-procedure
Reduction in headache intensity will be recorded using numeric rating scale (NRS). Each patient will be instructed about pain assessment with NRS score. NRS (0 represents "no pain" while 10 represents "the worst pain imaginable").
3 secondary outcomes
Migraine disability assessment score
Time frame: 3 months post-procedure
Headache duration
Time frame: 3 months post-procedure
Headache frequency
Time frame: 3 months post-procedure
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 May 2025.
- Individual participant dataSharing planned: Yes. The data will be available upon a reasonable request from the corresponding author after the end of study for one year.
Related trials for Greater Occipital Nerve Block
Not yet recruiting
Effect of Bilateral Greater Occipital Nerve Block on Headache After Intracranial Aneurysm Coiling
Intracranial Aneurysm, Postoperative Pain
RecruitingPhase 3
Dexmedetomidine Use for Greater Occipital Nerve Block in Pediatric Posterior Fossa Tumor Surgery.
Posterior Fossa Tumor
Recruiting
Greater Occipital Nerve Block for Migraine With Medication Overuse Headache
Migraine Disorders, Medication Overuse Headache
RecruitingPhase 2
Greater Occipital Nerve Blockade in Veterans With Post-concussion Headache: Sub-study 2
Post-Traumatic Headache
Not yet recruitingPhase 4
Efficacy of Ultrasound-Guided Combined Greater Occipital Nerve Block and Greater Auricular Nerve Block Versus Greater Occipital Nerve Block Alone in the Management of Chronic Migraine
Chronic Migraine Headache
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Greater occipital nerve blockade and Sphenopalatine ganglion blockade in people with Greater Occipital Nerve Block and Sphenopalatine Ganglion Block, run by New Valley University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 30 May 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Degree of headache intensity (time frame: 3 months post-procedure). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 May 2025.